FAP Inhibitor

DOTA-2P(FAPI)2 is a dimeric FAP (fibroblast activation protein) that can be used as a PET imaging agent and a tracer for tumor therapy.

SB03178 is a fibroblast activation protein-alpha (FAP) inhibitor. SB03178 can be conjugated with DOTA and can be used for cancer research.

FAP-IN-1 is a fibroblast activation protein (FAP) inhibitor with an IC₅₀ value of 3.3 nM. FAP-IN-1 can be used for the research of cancer.

FAP-IN-9 (compound P12) is a fibroblast activation protein (FAP) inhibitor with an IC₅₀ of 0.38 nM against human FAP. FAP-IN-9 functionally inhibits FAP activity, and its specific binding is verified by in vitro and in vivo blocking assays. FAP-IN-9 forms stable complexes and acts as a tumor-targeting agent. When labeled with ^99mTc, FAP-IN-9 serves as a SPECT probe and is applicable to research related to glioblastoma.

FAP Ligand-4 is an FAP inhibitor with an IC₅₀ of 20.2 nM for human FAP. FAP Ligand-4 can be used in cancer and inflammation-related studies.

QI-18 is a fibroblast activation protein (FAP) inhibitor with the IC₅₀ of 0.50 nM, which is a 6.5-fold increase in potency over that of UAMC-1110 (HY-100684，IC₅₀ of 3.25 nM). QI-18 can be used to synthesize high tumor selectivity and high dose radiotracers for the diagnosis and study of tumors.

FAP-IN-5 (Compound 4a) is an FAP inhibitor with an IC₅₀ of 1.7 nM. FAP-IN-5 can be used in the research of tumor positron emission tomography (PET) imaging.

Zilganersen sodium scrambled negative control is the sequence scrambled negative control of Zilganersen sodium.

Fas C-Terminal Tripeptide is a C-terminal tripeptide of Fas. Fas C-Terminal Tripeptide shows the inhibitory effect on Fas/FAP-1 binding.

3BP-4089 is a highly efficient fibroblast activation protein (FAP) targeting peptide. 3BP-4089 is often conjugated with radionuclides for tumor diagnosis and research.

FAP-IN-6 (Compound 21) is a selectivity FAP inhibitor with an IC₅₀ of 13 pM. FAP-IN-6 has a high metabolic stability. FAP-IN-6 labeled with 18F can be used as a positron emission tomography (PET) tracer. FAP-IN-6 can be used for microenvironment of cancers research.

FAPI-P8PN is a fibroblast activation protein (FAP) inhibitor (IC₅₀=3.6 nM). FAPI-P8PN is promising for research of FAP-overexpressing solid tumors.

FAP-IN-8 (Compound 12i) is a potent inhibitor of PREP and FAP, with pIC₅₀ values ​​of 8.99 and 10.08 for FAP and PREP, and IC₅₀ values ​​of 1 and 0.08 nM, respectively. FAP-IN-8 may be used in cancer research.

FAP-IN-7 (Compound 5b) is a FAP

BR103354 is an orally active, selective fibroblast activation protein (FAP) inhibitor with an IC₅₀ value of 14 nM against hFAP. BR103354 restores the levels of phosphorylated ERK and Glut1 that are reduced by co-treatment with hFGF21 and FAP, decreases non-fasting blood glucose concentrations, improves glucose tolerance, and reduces hepatic triglyceride content. BR103354 ameliorates hepatic steatosis and hepatic fibrosis. BR103354 can be used in the research of type 2 diabetes and non-alcoholic steatohepatitis.

DOTA-NI-FAPI-04 is a FAP inhibitor (IC₅₀ = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as 68Ga and 177Lu) through DOTA to produce radioactive probes ([68Ga]Ga/DOTA-NI-FAPI-04 and [177Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact.

OncoFAP-EN-DOTAGA is a FAP (fibroblast activation protein) targeting conjugate compound. OncoFAP-EN-DOTAGA can chelate radioactive isotopes (such as ) Ga-68 or fluorescent agent and can be used as a probe with targeting binding functions.

I-FAPI-04 prodrug-1 is a prodrug of I-FAPI-04, which is an inhibitor targeting fibroblast activation protein (FAP). I-FAPI-04 prodrug-1 can be used as a radioactive tracer in cancer.

UAMC-1110 (Standard) is the analytical standard of UAMC-1110 (HY-100684). This product is intended for research and analytical applications. UAMC-1110 is a highly potent and selective inhibitor of fibroblast activation protein (FAP) with an IC50 of 3.2 nM. UAMC-1110 also inhibits prolyl oligopeptidase (PREP) with an IC50 of 1.8 μM.

3BP-3580 is a fibroblast activation protein (FAP) inhibitor (pIC₅₀: 8.6), and can be used for cancer research.